ArticleThe review of diabetic studies : RDS2008
Stem cell therapy to treat diabetes mellitus.
Article in The review of diabetic studies : RDS, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 18 citations in OpenAlex.
- Metabolomics and Cell Therapy in Diabetes Mellitus.International journal of molecular and cellular medicine · 2019Review
- Direct differentiation of insulin-producing cells from human urine-derived stem cells.International journal of medical sciences · 2019Article
- Mechanistic Insight and Management of Diabetic Nephropathy: Recent Progress and Future Perspective.Journal of diabetes research · 2017Review
- Development of a tree shrew metabolic syndrome model and use of umbilical cord mesenchymal stem cell transplantation for treatment.Cytotechnology · 2016Article
- Bone marrow derived stem cell therapy for type 2 diabetes mellitus.Stem cell investigation · 2016Article
- Islet-derived stem cells from adult rats participate in the repair of islet damage.Journal of molecular histology · 2012Article
- Genetic analysis of type 1 diabetes: embryonic stem cells as new tools to unlock biological mechanisms in type 1 diabetes.The review of diabetic studies : RDS · 2012Review
- Islet transplantation in type 1 diabetics using an immunosuppressive protocol based on the anti-LFA-1 antibody efalizumab.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2010Article
- Pancreatic stem/progenitor cells for the treatment of diabetes.The review of diabetic studies : RDS · 2010Review
- Generation of insulin-producing cells from pluripotent stem cells: from the selection of cell sources to the optimization of protocols.The review of diabetic studies : RDS · 2010Review
- Intravenous transplantation of very small embryonic like stem cells in treatment of diabetes mellitus.Avicenna journal of medical biotechnologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Transplantation of pancreatic islets offers a direct treatment for type 1 diabetes and in some cases, insulin-dependent type 2 diabetes. However, its widespread use is hampered by a shortage of donor organs. Many extant studies have focused on deriving beta-cell progenitors from pancreas and pluripotent stem cells. Efforts to generate beta-cells in vitro will help elucidate the mechanisms of beta-cell formation and thus provide a versatile in vivo system to evaluate the therapeutic potential of these cells to treat diabetes. Various successful experiments using beta-cells in animal models have generated extensive interest in using human embryonic stem cells to restore normoglycemia in diabetic patients. While new techniques are continually unveiled, the success of beta-cell generation rests upon successful manipulation of culture conditions and the induction of key regulatory genes implicated in pancreas development. In this review, we compare successfully conducted protocols, highlight essential steps and identify some of the remarkable shortfalls common to these methods. In addition, we discuss recent advancements in the derivation of patient-specific pluripotent stem cells that may facilitate the use of autologous beta-cells in stem cell therapy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.